BRAF and melanoma: This hinted towards contextual utilization of additional pro-apoptotic signals that purportedly bypass TP53 requirement.27 Because BRAF(V600E)-positive melanomas very frequently develop resistance to targeted BRAF signaling inhibitors, we additionally tested the potential benefit of AURKA-i in melanoma cell lines (451Lu_BR and WM983B_BR) that had developed resistance to BRAF inhibitor PLX-4032.